Furthermore, it has also been shown that increased CD4 T cells producing IL22 in tumor tissues are associated with tumor progression and poor prognosis of patients, which is consistent with our results in advanced (T3, T4 phase) gastric cancer [24]. This evidence concerns the gene IL22 and neoplasm.